Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study1
References (12)
- et al.
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)
Graefes Arch Clin Exp Ophthalmol
(2008) - et al.
The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide
Br J Ophthalmol
(2006) - et al.
Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections
Retina
(2009) - et al.
Complications in patients after intravitreal injection of bevacizumab
Acta Ophthalmol
(2008) - et al.
Acute intraocular inflammation after intravitreous injections of bev-acizumab for treatment of neovascular age-related macular degeneration
Ophthalmology
(2008) - et al.
Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)
Br J Ophthalmol
(2009)
Cited by (30)
Drug-Induced Uveitis: Part 2: Cidofovir, Rifabutin, Sulfonamides, Bisphosphonates, Fluoroquinolones, Intravitreal Anti-Vascular Endothelial Growth Factor, and Topical Antiglaucoma Medications
2020, Advances in Ophthalmology and OptometryCitation Excerpt :So far, no other large-scale study data exist regarding cross-reactivity between these 3 agents. Other proposed mechanisms for postinjection inflammation include a toxic reaction to the excipient in the bevacizumab and ranibizumab formulations, contaminants from manufacturing the anti-VEGF or repackaging bevacizumab, or products/cells from the ocular surface that are inoculated into the eye at the time of the injection [90,96–98]. In preclinical and early clinical studies, a lyophilized formulation of ranibizumab might have been responsible for the intraocular inflammatory response; this formulation is no longer used [99].
Canadian expert consensus: Optimal treatment of neovascular age-related macular degeneration
2012, Canadian Journal of OphthalmologyCitation Excerpt :Clusters of cases of severe intraocular inflammation following intravitreal administration of bevacizumab have also been reported.61-64 Some of them had very poor visual outcomes.64 In a recent retrospective cohort study in the United States that included almost 147 000 Medicare beneficiaries with claims for AMD, ranibizumab treatment was associated with a significantly lower risk for mortality compared to PDT (hazard ratio [HR] 0.85; 99% CI, 0.75-0.95) or to pegaptanib (HR 0.84; 99% CI, 0.74-0.95); for myocardial infarction compared to PDT (HR 0.73; 99% CI, 0.58-0.92); as well as for stroke compared to PDT (HR 0.83; 99% CI, 0.69-0.99); and to bevacizumab (HR 0.81; 99% CI, 0.68-0.98).65
Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections
2012, Canadian Journal of OphthalmologyCitation Excerpt :Only 1 case of AII occurred in a patient following ranibizumab injection, and it was not associated with vision loss at the end of follow-up. Patients with AII secondary to bevacizumab lost an average 6.1 lines of visual acuity by the end of follow-up.8 Prior to the CATT trial, the only head-to-head comparisons between bevacizumab and ranibizumab were small retrospective chart reviews13–17 or even smaller prospective studies,18,19 none of which found significant differences between the 2 agents with respect to ocular or systemic adverse effects.
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
2011, Survey of OphthalmologyShort-term safety evaluation of resident-performed intravitreal injection
2021, Journal of Korean Ophthalmological Society
- 1
This article has been peer-reviewed.